3,4-Methylenedioxymethamphetamine (MDMA) affects monoaminergic pathways that play a critical role in sleep-wake cycles. Dopaminergic mechanisms are thought to mediate the sleep-disrupting effects of stimulant drugs. However, the mechanisms underlying the effects of MDMA on sleep-wake cycles and the effects of R(-) MDMA, a stereoisomer that lacks dopaminergic activity, on sleep remain unknown. The aim of the present study was to investigate the effects of racemic MDMA and R(-) MDMA on daytime activity and sleep-like parameters evaluated with actigraphy in adult rhesus macaques (Macaca mulatta, n ϭ 6). Actiwatch monitors were attached to the monkeys' collars and actigraphy recording was conducted during baseline conditions and after the administration of acute intramuscular injections of saline (vehicle), racemic MDMA (0.3, 1.0, or 1.7 mg/kg), or R(-) MDMA (0.3, 1.0, or 1.7 mg/kg) at 9 or 16 h (3 h before "lights off"). Morning treatments had no effects on sleep-like parameters. Racemic MDMA decreased general daytime activity during the first hour after injection and increased daytime activity at 3 hr posttreatment. Although afternoon administration of racemic MDMA increased sleep latency, it improved other sleep parameters, decreasing wake time after sleep onset (WASO) and increasing sleep efficiency for subjects with low baseline sleep efficiency. Afternoon treatment with R(-) MDMA improved sleep measures, increasing sleep efficiency and decreasing sleep latency and WASO, while having no effects on daytime activity. The stimulant and sleep-disrupting effects of racemic MDMA are likely mediated by dopaminergic and noradrenergic mechanisms, while serotonergic pathways appear to be involved in the sleep-promoting effects of MDMA.
Ecstasy is a commonly used recreational drug, with the most recent edition of the World Drug Report describing nearly 19.4 million global users (United Nations Office on Drugs and Crime, 2016) . Racemic (Ϯ)3,4-methylenedioxymethamphetamine (MDMA), the active component of ecstasy, is an amphetamine derivative that has stimulant, mood-enhancing, prosocial, and hallucinogen-like effects (Harris, Baggott, Mendelson, Mendelson, & Jones, 2002; Pitts, Curry, Hampshire, Young, & Howell, 2018; Shulgin, 1986) . Because of those effects, recent studies have investigated the therapeutic utility of racemic MDMA for the treatment of psychiatric disorders such as social anxiety, autism, and posttraumatic stress disorder (PTSD), with encouraging results (Amoroso & Workman, 2016; Danforth, Struble, Yazar-Klosinski, & Grob, 2016; Mithoefer et al., 2013 Mithoefer et al., , 2016 Pitts et al., 2018; YazarKlosinski & Mithoefer, 2017; Young, Andero, Ressler, & Howell, 2015 . However, the broad pharmacological actions of racemic MDMA translate not only into therapeutic efficacy, but also into the generation of adverse effects and abuse liability (Hardaway, Schweitzer, & Suzuki, 2016) .
The broad effects of racemic MDMA are mediated mainly by serotonin neurotransmission, as it has high affinity for the serotonin transporter (SERT), causing significant increases in extracellular serotonin (Berger, Gu, & Azmitia, 1992) . However, the complexity of effects generated by racemic MDMA seems to be influenced by the differential effects of its stereoisomers. The psychomotor stimulant and dopamine-releasing effects of racemic MDMA have been attributed to S(ϩ) MDMA, while R(-) MDMA has been shown to contribute to its hallucinogen effects through serotonergic mechanisms (Baker et al., 1995; Glennon, Yousif, & Patrick, 1988; Murnane, Murai, Howell, & Fantegrossi, 2009 .
The stimulant nature of racemic MDMA and the putative role of serotonin in sleep (Rancillac, 2016) have prompted researchers to investigate the effects of racemic MDMA on sleep-wake patterns. Racemic MDMA-induced sleep disruption has been reported in current and former chronic MDMA users (Allen, McCann, & Ricaurte, 1993; Carhart-Harris, Nutt, Munafò, & Wilson, 2009; Taurah, Chandler, & Sanders, 2014) . Acute racemic MDMA administration has also been shown to increase wakefulness and disrupt objective sleep measures in rodents (Balogh et al., 2004) , and to increase subject-rated levels of sleeplessness and restless sleep in humans (Baylen & Rosenberg, 2006; Huxster, Pirona, & Morgan, 2006) . In what seems to be the only study to date investigating the effects of acute MDMA on objective sleep measures in humans, a preliminary study with 7 MDMA-using participants showed altered sleep architecture after acute MDMA administration (Randall, Johanson, Tancer, & Roehrs, 2009) . Acute MDMA shortened sleep primarily by increasing sleep latency, also reducing slow wave sleep (SWS) and suppressing REM sleep (Randall et al., 2009 ). However, no study to date has evaluated objective sleep-related effects of acute racemic MDMA in nonhuman primates or the effects of MDMAs stereoisomers on sleep. Because sleep architecture in rhesus monkeys strongly resembles that of humans, this is a unique animal model for human sleep (Daley, Turner, Freeman, Bliwise, & Rye, 2006) . More important, studies have also shown that the effects of psychostimulant drugs on sleep are also similar in humans and rhesus monkeys (Ballard, Weafer, Gallo, & de Wit, 2015; .
The aim of the present study was to investigate the effects of racemic MDMA on daytime activity and sleep-like parameters evaluated with actigraphy in adult rhesus macaques. Based on the marked serotonergic effects of racemic MDMA, it has been suggested that serotonergic mechanisms mediate chronic MDMAinduced sleep disruption (for review, see Parrott, 2013) . However, studies indicate that the sleep-disrupting effects of stimulant drugs seem to be mediated by dopaminergic mechanisms (Andersen et al., 2010; Murnane et al., 2013) . Thus, in the present study we also investigated the effects of R(-) MDMA, a stereoisomer that lacks dopaminergic activity (Murnane, Fantegrossi, Godfrey, Banks, & Howell, 2010) , on daytime activity and actigraphy-based sleeplike measures to shed light into the mechanisms underlying the effects of MDMA on sleep-wake cycles.
Method Subjects
Five adult female (RDn8, RNb7, RZs9, RVm8, and RKf9) and one adult male (RJl8) rhesus monkeys (Macaca mulatta) weighing 8 -16 kg, served as subjects for the studies. Animals were fitted with collars (Primate Products) before the initiation of the studies. Each subject was individually housed in stainless steel home cages and fed Purina monkey chow (Ralston Purina, St. Louis, MO), supplemented with fruit and vegetables daily. Water was continuously available in the colony. Environmental enrichment was provided on a regular basis. The colony was maintained at an ambient temperature of 22 Ϯ 2°C at 45-50% humidity, and the lights were set to a 12-h light/dark cycle (lights on at 7h; lights off at 19h). All subjects had a long history of exposure to psychostimulants (Andersen, Diaz, Murnane, & Howell, 2013; Berro, Andersen, Tufik, & Howell, 2016 Berro, Perez Diaz, Maltbie, & Howell, 2017; Perez Diaz, Andersen, Rice, & Howell, 2017) . Subjects RZs9, RVm8, and RJl8 had at least 4 years of experience on methamphetamine self-administration before this study. Subject RDn8 had a previous history (ϳ3 years) of cocaine self-administration, and together with subject RNb7 had a history of intravenously (i.v.) psychostimulant treatments (once a week, every other week, for approximately 5 years) during in vivo microdialysis studies. Subject RKf9 had a history of occasional (every other week) psychostimulant exposure during awake functional magnetic resonance imaging (fMRI) scans for the previous 3 years. All protocols and animal care and handling strictly followed the National Institutes of Health Guide for the Care and Use of Laboratory Animals (8th edition, revised 2011) and the recommendations of the American Association for Accreditation of Laboratory Animal Care, and were approved by the Institutional Animal Care and Use Committee of Emory University. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
Actigraphy-Based Daytime Activity and Sleep Parameters
Actiwatch sensors (Mini Mitter, Bend, OR) were used to assess daytime and nighttime activity, as previously described (Andersen et al., 2010 (Andersen et al., , 2013 Murnane et al., 2013) . Briefly, the Actiwatch device consisted of an omni-directional sensor that is sensitive to motion (recorded as activity counts). The monitors were programmed to record the total piezo-electric voltage generated over the preceding 60 s (i.e., epoch length ϭ 60 s). The devices record the intensity, amount, and duration of movement in all three planes. Subjects had been adapted to wearing the activity monitors and trained to cooperate with the attachment of the sensor in their collars while seated in primate chairs (Primate Products). Daytime activity data generated activity counts/hour. Nighttime activity data generated the following sleep-like behavior parameters: sleep efficiency (i.e., the percentage of the dark phase spent sleeping); sleep latency (i.e., the time between "lights off" at 19 h and the first sleep bout); wake time after sleep onset (WASO, i.e., the time spent awake from sleep onset to "lights on" at 7 h). All parameters were calculated using the Actiware Sleep 3.4 software program (Mini-Mitter). Sleep measurements were automatically calculated from the underlying activity counts using a temporal smoothing algorithm on the basis that sleeping or wakefulness are continuous behaviors. The Actiware analysis software automatically inferred sleep-like parameters from activity counts during each 60-s epoch by comparing the sum of the activity counts in that epoch and neighboring epochs to a predefined criterion. The specific formula used is the sum of the activity in the epoch under evaluation, plus the activity in the epochs immediately before and after the epoch under evaluation Times 1/5, plus the activity in the epochs that occurred two epochs before and after the epoch under evaluation Times 1/25.
Protocol Design
Before the beginning of drug treatments, Actiwatches were attached to the monkeys' collars and baseline sleep-like behavior and daytime activity were measured for 1 week. Actigraphy recording continued for the duration of the treatments. Each subject was administered an intramuscular injection of saline (vehicle), racemic MDMA (0.3, 1.0 or 1.7 mg/kg) or R(-) MDMA (0.3, 1.0, or 1.7 mg/kg) at 9 or 16 h (3 h before the beginning of the dark period) on distinct days with at least 2 days between each treatment. The doses of racemic MDMA and R(-) MDMA were chosen based on previous studies from our laboratory investigating the behavioral, endocrine, and neurochemical effects of racemic MDMA and R(-) MDMA in rhesus monkeys McClung, Fantegrossi, & Howell, 2010; Murnane et al., 2010; Murnane, Kimmel, Rice, & Howell, 2012) . A 1-week baseline period was given between sets of treatments (racemic MDMA or R(-) MDMA, morning or afternoon). Except for subject RJl8, all other subjects were housed in the same housing room. All experiments were carried out contemporaneously and baseline sleep data were collected during the same week for all animals. During the treatment phase, the order of drug treatments, including vehicle treatments, and doses was randomized and counterbalanced across subjects, minimizing any potential influences of one subject's sleep alterations over others.
Data Analysis
Baseline data were combined across a 5 day span of time. Sleep data were analyzed using one-way repeated-measures (RM) analysis of variance (ANOVA) corrected for multiple comparisons using Dunnett's test. Daytime activity data were analyzed using two-way RM ANOVA (time and treatment factors) corrected for multiple comparisons using Dunnett's test. Correlational analyses were conducted using Pearson's Correlation. All graphical data presentations were created using Prism 5 (GraphPad Software), and all statistical tests were performed using PASW Statistics 18 (SPSS Statistics Software). Significance was accepted at an ␣ of 0.05.
Results

Sleep-Wake Pattern
Sleep-like measures. Sleep-like measures are presented as normalized data (percentage of baseline). Individual-subject baseline data are presented in Table 1 . One-way RM ANOVA showed no significant differences between treatment conditions for sleep efficiency (SE), sleep latency (SL), or WASO when subjects were given morning (9 h) treatments with racemic MDMA (SE: [F(3, 12) Figure 1F ). One-way RM ANOVA corrected for multiple Note. F ϭ female rhesus monkey; M ϭ male rhesus monkey; WASO ϭ wake time after sleep onset. Data are expressed as mean Ϯ SD. This document is copyrighted by the American Psychological Association or one of its allied publishers.
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comparisons using Dunnett's test showed significant differences between treatment conditions for SE, SL, and WASO when subjects were given afternoon (16 h Figure 2F ). While having no significant effects on SE (Figure 2A ), afternoon treatment with racemic MDMA dosedependently increased SL ( Figure 2B ) and decreased WASO (Figure 2C ). Afternoon treatment with R(-) MDMA improved outcomes for all sleep-like measures, inducing a dose-dependent increase in SE ( Figure 2D ), decrease in SL ( Figure 2E ) and decrease in WASO ( Figure 2F ). Correlational analysis showed a negative correlation between baseline SE and percent change in SE after afternoon treatment with 1.7 mg/kg racemic MDMA (r ϭ Ϫ0.98, p Ͻ .001), suggesting that the lower the subject's baseline SE, the higher the change in SE after racemic MDMA afternoon treatment. In fact, individual subject data show a dosedependent increase in SE after afternoon racemic MDMA for animals with low, but not high, baseline SE ( Figure 3A) . A significant correlation was also observed for SE after afternoon treatment with 1.7 mg/kg R(-) MDMA (r ϭ Ϫ0.99, p Ͻ .0001), with R(-) MDMA dose-dependently increasing SE for all subjects ( Figure 3D This document is copyrighted by the American Psychological Association or one of its allied publishers.
general home-cage activity, with 1.7 mg/kg racemic MDMA significantly decreasing daytime activity compared with vehicle (Figure 4A ). While daytime activity returned to baseline levels at the second hour posttreatment, 1.7 mg/kg racemic MDMA significantly increased general home-cage activity at the third hour after injection (18 -19 h; Figure 4A ). No significant differences were observed for daytime activity measures after afternoon treatment with R(-) MDMA ( Figure 4B ), with two-way RM ANOVA showing no effect of time (F(2, 8) ϭ 3.48, p Ͼ .05) or treatment (F(3, 12) ϭ 0.4, p Ͼ .05). Analysis of the daytime activity on the days after nighttime MDMA treatments showed no significant differences compared with baseline (data not shown).
Discussion
In the present study, we investigated the effects of racemic and R(-) MDMA on daytime activity and sleep-like behavior generated by actigraphy in adult rhesus monkeys. Morning treatment with either compound had no effects on sleep-like parameters. Treatment with racemic MDMA decreased general daytime activity during the first hour after injection, while showing daytime stimulant effects at 3 hr posttreatment. In agreement with the daytime stimulant effects, afternoon treatment with racemic MDMA induced a marked dose-dependent increase in SL in all subjects, with no significant differences on SE. Individual subject data as well as correlational analysis indicated, however, that racemic MDMA had differential effects on SE depending on subjects' baseline sleep parameters, improving this sleep measure for subjects with low baseline SE. Accordingly, a dose-dependent decrease in WASO was observed after afternoon racemic MDMA administration. Afternoon treatment with R(-) MDMA improved sleep measures for all subjects, increasing SE and decreasing SL and WASO, having no effects on general home-cage daytime activity.
The biphasic effects of racemic MDMA on daytime activity observed in the present study had been previously reported in rhesus monkeys. Crean and colleagues reported decreased daytime activity during the first hour after racemic MDMA injection and increased general home-cage activity at 3 hr posttreatment. Similarly, a recent study from our This document is copyrighted by the American Psychological Association or one of its allied publishers.
group has shown decreased general daytime activity during the first hour after racemic MDMA administration in squirrel monkeys (Pitts et al., 2018) . More important, R(-) MDMA, a stereoisomer that has no effects on dopamine release , did not alter daytime activity at any time-point after drug administration, suggesting that the stimulant effects of racemic MDMA are likely because of its dopamine-releasing effects. However, the present findings suggest that, contrary to what is observed for other psychostimulant drugs such as amphetamine (Murnane et al., 2013) and methamphetamine (Berro, Andersen, Tufiket al. 2017) , the stimulant effects of racemic MDMA may take up to 2 hr to emerge. Racemic MDMA shows a lower dopamine to serotonin release profile compared with other psychostimulant compounds (Rothman et al., 2001) , that could explain the unique effects of racemic MDMA on daytime activity. Consistent with the daytime stimulant effects emerging at 3 hr posttreatment, afternoon treatment with racemic MDMA induced a marked dose-dependent increase in SL. The present findings are in agreement with previous studies showing that increased SL is the main sleep-related effect of acute racemic MDMA administration. The effects of MDMA on sleep architecture have been reported in rodents, showing increased wakefulness and decreased SWS and REM sleep time (Baylen & Rosenberg, 2006) . A preliminary study in humans has also reported reduced SWS and REM sleep time after acute MDMA administration, with shortened sleep primarily because of increased SL, when participants were given an 8-hr sleep opportunity (Randall et al., 2009) .
Both in the studies with rodents (Balogh et al., 2004) and in the present study, racemic MDMA-induced delayed sleep onset was associated with increased general daytime activity, suggesting that the effects of racemic MDMA on SL are associated with its daytime stimulant effects. Similar effects have been previously reported for other psychostimulant drugs, such as amphetamine (Murnane et al., 2013) and methamphetamine (Andersen et al., 2013; Berro et al., 2016; Berro, Andersen, Tufik, et al., 2017) . More important, in the study by Crean and colleagues , as well as in other studies by the same group Taffe et al., 2006; Von Huben et al., 2007) , racemic MDMA has been shown to induce significant increases in body temperature in rhesus monkeys, an effect that can last for up to 4 hr . Although the authors show that this effect was not coupled to MDMA-induced changes in daytime activity , circadian body temperature rhythms are a signaling pathway for the modulation of sleep and wakefulness (VanSomeren, 2000) . Changes in core body temperature have a major influence on sleep This document is copyrighted by the American Psychological Association or one of its allied publishers.
regulation and are known to affect the ability to initiate sleep (Romeijn et al., 2012) . Thus, MDMA-induced hyperthermia could also contribute to the effects of racemic MDMA on SL. Corroborating this hypothesis, a recent study has shown that R(-) MDMA did not increase body temperature in rodents (Curry, Young, Tran, Daoud, & Howell, 2018) , which is in line with the lack of negative effects of R(-) MDMA on SL observed in the present study. Because other psychostimulant drugs, such as methamphetamine, also induce hyperthermia in rhesus monkeys , the effects of those drugs on SL could also be attributable to their effects on body temperature in addition to their stimulant effects. Although racemic MDMA and other amphetamine-type drugs exert similar effects on SL, those drugs seem to exert distinct effects on other sleep parameters. In our previous studies, amphetamine and methamphetamine administration also impaired sleep by decreasing SE and increasing sleep fragmentation (Andersen et al., 2013; Berro et al., 2016; Berro, Andersen, Tufik, et al., 2017; Murnane et al., 2013) . While MDMA had no significant effects on sleep fragmentation (data not shown), it significantly decreased WASO, also increasing SE in animals with low baseline SE.
As previously mentioned, one of the main differences between MDMA and other psychostimulant drugs is that racemic MDMA acts predominantly as a serotonin releaser, showing a low dopamine to serotonin release profile (Rothman et al., 2001) . Thus, we propose that the stimulant effects of MDMA on daytime activity are a consequence of the dopamine-releasing effects of racemic MDMA, and that increased dopamine levels impair sleep onset when racemic MDMA is given close to bedtime (afternoon treatments). However, racemic MDMA-induced serotonin release would also activate sleep-promoting serotonergic pathways and improve sleep measures after sleep onset and throughout the night. Because racemic MDMA also potentiates the activity of other neurotransmitter systems, it cannot be ruled out that other neural pathways might also be modulating its effects on daytime activity and sleep. For instance, racemic MDMA also increases brain levels of norepinephrine (NE), and evidence suggests that this effect is predominantly modulated by S(ϩ) MDMA (Steele, Nichols, & Yim, 1987; Verrico, Miller, & Madras, 2007) . NE is involved in the ascending arousal system, and high extracellular NE levels enhance neurotransmission along wake-promoting pathways (Mitchell & Weinshenker, 2010) . Thus, in addition to changes in dopamine and serotonin neurotransmission, increased NE levels could also account for the increased SL observed after racemic MDMA administration.
Regarding the effects of serotonin on sleep, previous studies in humans have shown that acute treatment with the serotonin releaser fenfluramine and the serotonin reuptake inhibitor citalopram had no effects on SE, SL, or WASO in humans (Myers et al., 1993; Neckelmann, Bjorvatn, Bjørkum, & Ursin, 1996) . However, changes in sleep architecture were observed after the administration of both compounds, including decreased percentage of time spent in slow wave sleep and changes on sleep power spectral parameters, with citalopram also decreasing percentage of time spent in REM sleep (Myers et al., 1993; Neckelmann et al., 1996) . Those findings suggest that MDMA and R(-) MDMA have a unique pharmacological profile that engenders sleep-inducing effects, but also emphasize the importance of further studies investigating the effects of MDMA and R(-) MDMA on sleep architecture. The same study by Neckelmann and colleagues (1996) also showed that the effects of chronic treatment with citalopram on sleep parameters were different from those of acute citalopram administration, with more prominent changes in sleep architecture after chronic treatment. Because the chronic use of sedativehypnotics is also known to induce tolerance (Santos & Olmedo, 2017) , the investigation of the effects of acute doses is a limitation of the present study, and future studies investigating the effects of chronic MDMA and R(-) MDMA on sleep are warranted.
Several studies have investigated the role of serotonin in the regulation of sleep-wake cycles, and yet the serotonergic pathways regulating sleep remain incompletely understood. Studies suggest that serotonin can have both an inhibitory and an excitatory effect in the ventrolateral preoptic nucleus (VLPO), the main sleep center in the brain, depending on the type of neuron that is being targeted (Rancillac, 2016) . More important, serotonin 5-HT 2A and 5-HT 2C receptors seem to be the most frequent serotonin receptors in VLPO neurons (Sangare, Dubourget, Geoffroy, Gallopin, & Rancillac, 2016) , and studies suggest that 5-HT 2A receptor antagonists and 5-HT 2C receptor agonists have sedative effects (Adam & Oswald, 1989; Landolt et al., 1999; Monti, 2011; Morairty, Hedley, Flores, Martin, & Kilduff, 2008; Rosenberg et al., 2008; Sangare et al., 2016) . In fact, we have previously shown that antagonism of 5-HT 2A receptors as well as activation of 5-HT 2C receptors decrease the sleep-disrupting effects of amphetamine- This document is copyrighted by the American Psychological Association or one of its allied publishers. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
type stimulants in rhesus monkeys (Murnane et al., 2013; Perez Diaz et al., 2017) . Thus, the sleep-promoting effects of racemic MDMA appear to be regulated by serotonergic pathways. By acting exclusively through serotonergic mechanisms, R(-) MDMA would be expected to have sleep-promoting effects without the detrimental effects on daytime activity and on SL observed with racemic MDMA. Furthermore, R(-) MDMA has high affinity for 5-HT 2 receptors (Lyon, Glennon, & Titeler, 1986) , that could contribute to the sleep-inducing effects observed in the present study after R(-) MDMA afternoon administration. The half-life of intravenous MDMA in rhesus monkeys is approximately 90 min, reaching maximum plasma concentration at 5 min after injection (Banks et al., 2007) . Accordingly, serotonin and prolactin levels induced by racemic MDMA return to baseline levels 90 min postinjection (Murnane et al., 2012) . Its metabolites, on the other hand, are still detected in the plasma for at least 4 hr after drug administration (Banks et al., 2007) , suggesting that the effects of racemic MDMA on sleep observed in the present study could be attributed to its metabolites. Regarding R(-) MDMA, to the best of our knowledge no studies to date have investigated its pharmacokinetics in rhesus monkeys. We have previously shown that serotonin and prolactin levels induced by R(-) MDMA return to baseline levels at 60 min after injection (Murnane et al., 2012) , indicating that the half-life of R(-) MDMA could be shorter than that of racemic MDMA. However, studies in rodents (Fitzgerald, Blanke, & Poklis, 1990 ) and humans (Fallon et al., 1999) have reported that the elimination half-life of R(-) MDMA is significantly longer than that of the S(ϩ) enantiomer. Further studies are warranted to determine the pharmacokinetic profile of R(-) MDMA in rhesus monkeys and the role R(-) MDMA and racemic MDMA metabolites on the effects of MDMA on sleep Because of its mood-enhancing and prosocial effects, recent studies have investigated the therapeutic utility of racemic MDMA for the treatment of psychiatric disorders such as social anxiety, autism, and posttraumatic stress disorder (PTSD), with encouraging results (Amoroso & Workman, 2016; Danforth et al., 2016; Mithoefer et al., 2013 Mithoefer et al., , 2016 Pitts et al., 2018; Yazar-Klosinski & Mithoefer, 2017; Young et al., 2015 Young et al., , 2017 . The broad pharmacological actions of racemic MDMA, however, translate not only into therapeutic efficacy, but also into the generation of adverse effects and abuse liability. Although it has never been studied in humans, racemic MDMA seems to have significant abuse potential (Hardaway et al., 2016) , being self-administered by rodents van de Wetering & Schenk, 2017) and nonhuman primates (Wang & Woolverton, 2007) . In addition, in the present study afternoon treatment with racemic MDMA induced stimulant effects and delayed sleep onset. Of importance for the treatment of PTSD, MDMA has been used in association with fear extinction (Amoroso & Workman, 2016; de Kleine, Rothbaum, & van Minnen, 2013; Young et al., 2015 Young et al., , 2017 , a learning strategy that requires appropriate memory consolidation, with compelling evidence suggesting that sleep actively supports longlasting memory formation (Feld & Born, 2017; Melo & Ehrlich, 2016) . Thus, the balance between benefit and risk is one of the major challenges for the clinical use of racemic MDMA.
Our findings show that morning treatment with racemic or R(-) MDMA had no effects on sleep-like parameters, suggesting that adverse side effects such as sleep impairment can be prevented by modulating the time of the day racemic MDMA is administered.
The present study also provides relevant insights into clinical practice by showing that R(-) MDMA improved sleep measures in rhesus monkeys without exerting stimulant effects on daytime activity. Thus, our findings suggest that R(-) MDMA could have therapeutic potential without inducing adverse effects, corroborating previous findings in rodents showing that R(-) MDMA has therapeutic effects in models of fear memory extinction and social interaction without exerting stimulant, thermogenic, and neurotoxic effects Pitts et al., 2018) . Although R(-) MDMA self-administration has been reported in rhesus monkeys (Fantegrossi, 2008) , opposing evidence suggests that the reinforcing effectiveness of racemic MDMA seems to derive primarily from S(ϩ) MDMA (Wang & Woolverton, 2007) . For instance, racemic and S(ϩ), but not R(-), MDMA were effective in inducing reinstatement of extinguished amphetamine self-administration . Further studies are warranted to determine the abuse liability as well as the therapeutic utility of R(-) MDMA in humans. As previously mentioned, a limitation of the present study was the lack of evaluation of electrophysiological parameters of sleep, and future studies are needed to investigate the effects of racemic MDMA and R(-) MDMA on sleep architecture. In addition to the potential applicability for the treatment of psychiatric disorders, our findings suggest that R(-) MDMA could be useful for the treatment of sleep impairment in the context of mood and anxiety disorders as well as PTSD.
